Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer

被引:16
作者
Ando, M
Ando, Y
Sugiura, S
Minami, H
Saka, H
Sakai, S
Shimokata, K
Hasegawa, Y
机构
[1] Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Japanese Res Cross Nagoya First Hosp, Dept Internal Med, Nakamura Ku, Nagoya, Aichi 4538511, Japan
[3] Natl Canc Ctr Hosp E, Kashiwa, Chiba 2770882, Japan
[4] Nagoya Univ, Sch Med, Clin Prevent Serv, Higashi Ku, Nagoya, Aichi 4610047, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1999年 / 90卷 / 02期
关键词
minimum life expectancy; non-small cell lung cancer; performance status; metastasis;
D O I
10.1111/j.1349-7006.1999.tb00740.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prognostic factors which can forecast short-term survival in patients with stage IV non-small cell lung cancer have not been well evaluated, Characteristics of such factors may be different from those for overall survival, and would be an important eligibility criterion for clinical trials of chemotherapy We retrospectively analyzed the data of 158 patients with stage IV non-small cell lung cancer whose performance status was 0, 1 or 2, Univariate and multivariate logistic regression models revealed demographic variables which significantly correlated with the survival at 8 or 12 weeks. The univariate model showed the following significant variables: T factor, N factor, number of organs with metastases, grade of performance status, weight loss within 6 months, evidence of metastasis either at bone or lymph node, and lactate dehydrogenase level. The subsequent multivariate model demonstrated that both grade of performance status under 2 and number of metastasized organs less than 3 are important factors for 8- or 12-week survival. The survival rate in patients meeting the two criteria (grade of performance status under 2 and number of metastasized organs less than 3) and in those meeting only one of them was 93% versus 80% at 8 weeks (P=0.030) and 88% versus 62% at 12 weeks (P<0.001), respectively. Grade of performance status and number of organs with metastases appear to be important prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.
引用
收藏
页码:249 / 253
页数:5
相关论文
共 12 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
EVANS C, 1985, LANCET, V1, P1204
[3]   LONG-TERM SURVIVORS IN METASTATIC NON SMALL-CELL LUNG-CANCER - AN EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY [J].
FINKELSTEIN, DM ;
ETTINGER, DS ;
RUCKDESCHEL, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (05) :702-709
[4]  
IHDE DC, 1992, NEW ENGL J MED, V327, P1434
[5]  
LEVENTHAL BG, 1988, RES METHODS CLIN ONC, P41
[6]   Revisions in the International System for Staging Lung Cancer [J].
Mountain, CF .
CHEST, 1997, 111 (06) :1710-1717
[7]   FREQUENCY AND PROGNOSTIC IMPORTANCE OF PRETREATMENT CLINICAL CHARACTERISTICS IN PATIENTS WITH ADVANCED NON SMALL-CELL LUNG-CANCER TREATED WITH COMBINATION CHEMOTHERAPY [J].
OCONNELL, JP ;
KRIS, MG ;
GRALLA, RJ ;
GROSHEN, S ;
TRUST, A ;
FIORE, JJ ;
KELSEN, DP ;
HEELAN, RT ;
GOLBEY, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (11) :1604-1614
[8]   PROGNOSTIC FACTORS FOR SURVIVAL IN ADVANCED NON-SMALL-CELL LUNG-CANCER - UNIVARIATE AND MULTIVARIATE ANALYSES INCLUDING RECURSIVE PARTITIONING AND AMALGAMATION ALGORITHMS IN 1,052 PATIENTS [J].
PAESMANS, M ;
SCULIER, JP ;
LIBERT, P ;
BUREAU, G ;
DABOUIS, G ;
THIRIAUX, J ;
MICHEL, J ;
VANCUTSEM, O ;
SERGYSELS, R ;
MOMMEN, P ;
KLASTERSKY, J .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1221-1230
[9]   A RANDOMIZED TRIAL OF THE 4 MOST ACTIVE REGIMENS FOR METASTATIC NON SMALL-CELL LUNG-CANCER [J].
RUCKDESCHEL, JC ;
FINKELSTEIN, DM ;
ETTINGER, DS ;
CREECH, RH ;
MASON, BA ;
JOSS, RA ;
VOGL, S .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :14-22
[10]  
SHEPHERD FA, 1994, SEMIN ONCOL, V21, P7